Table 1

Patient characteristics in the different treatment groups

Early methotrexate (MTX)Early biological+ MTXEarly biological (mono)All early patientsLate biological+ MTXALL
N49987546518396442483
Age (years)50.1 (13.1)49.6 (13.4)50.4 (13.2)49.9 (13.3)54.0 (11.8)51.0 (13.0)
Sex (% female)75.274.275.374.774.774.7
Duration of rheumatoid arthritis (years)0.9 (0.9)0.8 (0.9)0.9 (0.9)0.9 (0.9)10.0 (8.6)3.2 (6.0)
Rheumatoid factor (% positive)75.976.879.877.380.178.0
C reactive protein (CRP, mg/dL)3.50 (4.03)3.18 (3.47)3.93 (4.87)3.46 (4.02)2.42 (2.73)3.19 (3.76)
Erythrocyte sedimentation rate (ESR, mm/h)44.8 (27.0)48.6 (29.2)42.5 (26.8)46.1 (28.1)42.2 (23.1)45.9 (27.9)
Swollen joint count (0–28)12.6 (6.1)11.7 (6.0)14.2 (6.0)12.6 (6.1)13.0 (6.1)12.7 (6.1)
Tender joint count (0–28)15.3 (6.6)15.6 (6.9)16.0 (6.9)15.6 (6.8)15.0 (7.2)15.5 (6.9)
Patient global assessment (0–100 mm)61.4 (23.6)64.3 (23.7)63.1 (21.0)63.2 (23.0)55.4 (23.3)61.2 (23.4)
Evaluator global assessment (0–100 mm)63.7 (17.8)66.3 (18.3)63.8 (17.9)65.0 (18.1)60.4 (16.9)63.8 (17.9)
Visual Analogue Scale pain (0–100 mm)59.9 (23.5)63.6 (21.6)59.1 (23.6)61.5 (22.7)58.5 (21.9)60.7 (22.5)
Simplified Disease Activity Index43.9 (14.4)43.6 (14.6)46.8 (14.7)44.5 (14.6)42.1 (14.0)43.8 (14.5)
Clinical Disease Activity Index40.4 (12.7)40.4 (13.5)42.9 (12.8)41.0 (13.1)39.6 (13.1)40.7 (13.1)
Disease Activity Score 28—ESR6.46 (1.05)6.55 (1.07)6.54 (1.09)6.52 (1.07)6.10 (1.06)6.50 (1.07)
Disease Activity Score 28—CRP6.01 (0.98)6.02 (1.01)6.17 (1.01)6.06 (1.01)5.83 (0.96)6.00 (1.00)
Health Assessment Questionnaire1.50 (0.61)1.57 (0.67)1.48 (0.62)1.53 (0.64)1.49 (0.64)1.52 (0.64)
Total X-ray score (Sharp/Sharp v.d. Heijde)15.7 (18.9)11.7 (15.9)13.4 (16.4)13.2 (17.0)61.9 (58.6)25.6 (39.2)
  • Data are presented as means (SD) unless indicated otherwise.